Effects of adenosine and regadenoson on hemodynamics measured using cardiovascular magnetic resonance imaging

Figures

• 

  Fig. 1. Schematic of the study design. SAX = short axis projection; SSFPs = steady-state free precession sequences. For the purposes of analysis, hemodynamic, volumetric, and ejection fraction results obtained at the 15 min point following adenosine administration were used as the baseline values for regadenoson administration

• 

  Fig. 2. Heart rate changes following vasodilator administration: Temporal changes in heart rate from baseline following administration of adenosine (green line) and regadenoson (blue line). P-values shown represent differences in the magnitude of heart rate change at each time point between adenosine and regadenoson. The Post-vasodilator (VD) time point represents heart rates acquired immediately following vasodilator administration. Heart rate returned to baseline following adenosine infusion by the 10 min mark (p = 0.9397) whereas heart rate following regadenoson remained elevated compared with baseline at the 15 min mark (p = 0.0015)

• 

  Fig. 3. Changes in ejection fraction following vasodilator administration: Observed changes in left ventricular (LV) ejection fraction (LVEF) from baseline values following administration of adenosine (dashed line) and regadenoson (solid line) are shown in (a) and changes in right ventricular (RV) EF from baseline values are shown in (b). The Post-vasodilator time point represents short-axis cine data sets acquired immediately following vasodilator (VD) administration. P-values shown represent differences in the magnitude of EF change at each time point between adenosine and regadenoson. LVEF returned to baseline following adenosine infusion by the 10 min mark (p = 0.84) whereas LVEF following regadenoson remained elevated compared with baseline at the 15 min mark (p = 0.0015). Regarding RVEF (b), maximal impact of regadenoson occurred later than adenosine with adenosine returning to baseline by 15 min (p = 0.29). RVEF continued to be elevated at the 15 min mark following regadenoson administration (p = 0.016)

• 

  Fig. 4. Temporal changes in left ventricular (LV) volumes from baseline: Observed changes in left ventricular end-diastolic volume index (LVEDVi) from baseline values following administration of adenosine (green bar) and regadenoson (blue bar) are shown in (a) and left ventricular end-systolic volume index (LVESVi) from baseline values are shown in (b). The Post-vasodilator time point represents data sets acquired immediately following vasodilator (VD) administration. P-values adjacent to the zero gridline represent changes from baseline at each time point following administration of regadenoson (*) and adenosine (†). P-values shown at the bottom of the figure represent differences in the magnitude of change in LVEDVi (a) and LVESVi (b) at each time point between adenosine and regadenoson

• 

  Fig. 5. Patient symptoms following vasodilator administration: Patient reported symptoms experienced with administration of adenosine and regadenoson